No connection

Search Results

ABCL vs INNV

ABCL
AbCellera Biologics Inc.
NEUTRAL
Price
$3.49
Market Cap
$1.06B
Sector
Healthcare
AI Confidence
72%
INNV
InnovAge Holding Corp.
BEARISH
Price
$8.20
Market Cap
$1.11B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABCL
--
INNV
164.0
Forward P/E
ABCL
-4.53
INNV
24.12
P/B Ratio
ABCL
1.08
INNV
4.33
P/S Ratio
ABCL
14.08
INNV
1.22
EV/EBITDA
ABCL
-3.42
INNV
25.73

Profitability

Gross Margin
ABCL
-148.68%
INNV
68.08%
Operating Margin
ABCL
-63.72%
INNV
5.53%
Profit Margin
ABCL
-194.88%
INNV
0.71%
ROE
ABCL
-14.47%
INNV
1.18%
ROA
ABCL
-9.99%
INNV
2.92%

Growth

Revenue Growth
ABCL
788.2%
INNV
14.7%
Earnings Growth
ABCL
--
INNV
--

Financial Health

Debt/Equity
ABCL
0.15
INNV
0.33
Current Ratio
ABCL
11.32
INNV
1.26
Quick Ratio
ABCL
10.07
INNV
1.04

Dividends

Dividend Yield
ABCL
--
INNV
--
Payout Ratio
ABCL
0.0%
INNV
0.0%

AI Verdict

ABCL NEUTRAL

ABCL exhibits severe financial distress according to the Piotroski F-Score (1/9), indicating weak operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics—particularly a -194.88% profit margin and -14.47% ROE—highlight deep operational inefficiencies. Despite a 788.2% YoY revenue growth and strong earnings surprise history (average +30.86% over last 4 quarters), the company remains unprofitable and carries significant valuation risk. The current price of $3.49 trades at a steep 14.08 Price/Sales ratio, far exceeding sector averages, suggesting speculative pricing. Analysts' target price of $9.17 implies strong upside potential, but this is based on unproven profitability and high risk.

Strengths
Exceptional 788.2% YoY revenue growth, signaling strong market traction
Positive earnings surprise history (average +30.86% over last 4 quarters)
Strong recent Q/Q EPS growth (+84.2%) and year-over-year EPS improvement (+75.0%)
Risks
Piotroski F-Score of 1/9 indicates severe financial and operational weakness
Negative profit, operating, and gross margins across all metrics (-194.88%, -63.72%, -148.68%)
No Graham Number or intrinsic value estimate due to lack of profitability and negative earnings
INNV BEARISH

INNV exhibits a stable financial foundation with a Piotroski F-Score of 6/9, but it is currently suffering from a severe valuation disconnect. The current price of $8.20 trades at a massive premium to both the Graham Number ($1.46) and the growth-based Intrinsic Value ($0.35). While the forward P/E of 24.12 suggests a significant earnings recovery is expected, the trailing P/E of 164.00 and thin profit margins (0.71%) indicate the stock is priced for perfection. Combined with bearish insider sentiment and a technical trend of 0/100, the risk-to-reward ratio is unfavorable.

Strengths
Stable financial health indicated by Piotroski F-Score of 6/9
Strong gross margins of 68.07%
Low leverage with a Debt/Equity ratio of 0.33
Risks
Extreme overvaluation relative to Graham Number and Intrinsic Value
Dangerously thin net profit margins (0.71%)
Bearish insider activity (President selling shares)

Compare Another Pair

ABCL vs INNV: Head-to-Head Comparison

This page compares AbCellera Biologics Inc. (ABCL) and InnovAge Holding Corp. (INNV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile